Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05547321 · ClinicalTrials.gov registry record · Phase 1

Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.

A Phase 1 study of Advanced Solid Tumor, sponsored by Oncomatryx Biopharma S.L..

Recruiting
Registry status
Phase 1
Development phase
150
Enrollment target
9
Study locations

NCT05547321 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Oncomatryx Biopharma S.L.. The registered enrollment target is 150 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (22% lower). The trial reports 9 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05547321, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Oncomatryx Biopharma S.L..

RECRUITING
Registry status
Phase 1
Development phase
150 participants
Enrollment target
9
Study locations

Study Summary

Open-label, two parallel arm, multicenter, Phase 1 dose-escalation study to evaluate the safety and tolerability of OMTX705, both as monotherapy or in combination with pembrolizumab (Part 1) or tislelizumab (Part 2) in the treatment of patients with advanced or metastatic cancer in whom there is no available standard therapeutic option.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG Pembrolizumab
  • DRUG OMTX705

Study Locations (9)

Barcelona

  • Hospital Universitari Vall d'Hebron - Barcelona
  • ICO L'Hospitalet - L'Hospitalet de Llobregat

Madrid

  • Hospital 12 Octubre - Madrid
  • Hospital MD Anderson - Madrid

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Galicia

  • Hospital Clínico Universitario de Santiago - Santiago de Compostela

Guipúzcoa

  • Hospital Universitario de Donostia - San Sebastián

Navarre

  • Clínica Universitaria de Navarra - Pamplona

Other

  • Onkologikoa - San Sebastián

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2022-10-20
Est. Completion 2027-12
Phase Phase 1

Sponsor

Oncomatryx Biopharma S.L.

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05547321

The ClinicalTrials.gov registry entry for NCT05547321 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (22% lower). The listed sponsor is Oncomatryx Biopharma S.L., which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT05547321 reports 9 study locations spanning 7 distinct geographic areas - top geographies include Barcelona, Madrid, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05547321 about?

NCT05547321 is a clinical study titled "Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.". Open-label, two parallel arm, multicenter, Phase 1 dose-escalation study to evaluate the safety and tolerability of OMTX705, both as monotherapy or in combination with pembrolizumab (Part 1) or tislelizumab (Part 2) in the treatment of patients with advanced or metastatic cancer in whom there is no ...

What is the current status of trial NCT05547321?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2022-10-20. Estimated completion is 2027-12.

What conditions does trial NCT05547321 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT05547321?

The interventions under investigation include: Pembrolizumab (DRUG), OMTX705 (DRUG).

Who is sponsoring clinical trial NCT05547321?

This trial is sponsored by Oncomatryx Biopharma S.L., which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05547321 being conducted?

This trial has 9 study locations across Massachusetts, Barcelona, Galicia, Guipúzcoa, Madrid. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.